Documente Academic
Documente Profesional
Documente Cultură
Correspondence
Daniel Creamer.
E-mail: daniel.creamer@nhs.net
1.0 Purpose and scope
Accepted for publication
19 January 2016
The overall objective of the guidelines is to provide up-to-
date, evidence-based recommendations for the diagnosis and
Funding sources management of the full spectrum of StevensJohnson syn-
None. drome (SJS), toxic epidermal necrolysis (TEN) and SJSTEN
overlap in adults during the acute phase of the disease.
Conflicts of interest
J.K.G.D. has received grant/research support from Dompe and SiFi. M.R.A.-J. has done The document aims to: (i) offer an appraisal of all relevant
commissioned work for Genus Pharmaceuticals; received sponsorship from AbbVie, Jans- literature up to February 2016, focusing on any key develop-
sen-Cilag, Pfizer, Galderma and Steifel to attend conferences; has performed clinical trials ments; (ii) address important, practical clinical questions relat-
for Zymogenetics, Pfizer, Genentech, Johnson & Johnson, Centocor and Novartis; has
received grant/research support from Emblation; and has developed a nonprofit website, ing to the primary guideline objective, i.e. accurate diagnosis
www.drugrash.co.uk, to assist clinicians in the management of drug allergy. None of and identification of cases and suitable treatment; (iii) provide
the authors has received commercial support from the manufacturers of any medication guideline recommendations; and (iv) discuss areas of uncer-
used in the management of StevensJohnson syndrome/toxic epidermal necrolysis.
tainty, potential developments and future directions
D.C., S.A.W., P.D., H.Y.L., J.K.G.D., J.S., C.B.B., M.R.A.-J., K.M.T.W., G.A.E.W.,
SJS/TEN is rare and few healthcare professionals are confi-
M.P., A.V., R.V.M., G.W., M.S., D.B., P.W. and C.H.S. are members of the guideline
development group with technical support provided by L.S.E. and M.F.M.M. dent in the recognition and management of the disorder.
This is a new set of guidelines prepared for the British Association of Dermatologists There is widely divergent practice among different specialities
(BAD) Clinical Standards Unit, which includes the Therapy & Guidelines (T&G) Sub- and healthcare settings, and limited information on outcomes.
committee. Members of the Clinical Standards Unit that have been involved are P.M. These guidelines aim to provide recommendations on the
McHenry (Chairman T&G), J.R. Hughes, M. Griffiths, K. Gibbon, A.J. McDonagh,
D.A. Buckley, I. Nasr, V.J. Swale, C.E. Duarte Williamson, N.J. Levell, T. Leslie, E. diagnosis and management of SJS/TEN, to inform clinical
Mallon, S. Wakelin, S. Ungureanu, P. Hunasehally, M. Cork, K. Towers [British decision-making and, when justified by evidence, to standard-
National Formulary (BNF)], J. Donnelly (BNF), C. Saunders (British Dermatological ize practice. The breadth of this document should be sufficient
Nursing Group), L.S. Exton (BAD Information Scientist), A.G. Brain (BAD Clinical
Standards Administrator) and M.F. Mohd Mustapa (BAD Clinical Standards Manager). to assist clinicians of all relevant specialities in the manage-
ment of patients with SJS/TEN. The recommendations will
DOI 10.1111/bjd.14530
also inform pathways of care to optimize healthcare delivery
Produced in 2016 by the British Association of Dermatologists. NICE and highlight key areas of uncertainty for future research.
has accredited the process used by the British Association of Dermatolo-
gists to produce guidelines. Accreditation is valid for 5 years from May In these guidelines, the term SJS/TEN encompasses the full
2010 and has been extended by agreement to May 2016. More informa-
tion on accreditation, and full details of our accreditation, can be viewed spectrum of the disease, i.e. SJS, TEN and SJSTEN overlap
at www.nice.org.uk/accreditation.
(see section 7.2 for clinical definition of the separate entities).
The guideline is presented as a detailed review with
1194 British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1195
highlighted recommendations for practical use (see section specific targeted searches for hypersensitivity testing, causative
18.0), in addition to the development of a new patient infor- drugs, diagnostic and prognostic indicators, topical treatments,
mation leaflet [available on the British Association of Derma- oral/mouth, growth factors and granulocyte colony-stimulat-
tologists (BAD) website, www.bad.org.uk]. Unless otherwise ing factor (G-CSF), and analgesia. The lead authors screened
specified, recommendations apply to all forms of the disease. the identified titles, and those relevant for first-round inclu-
sion were selected for further scrutiny. All co-authors then
reviewed the abstracts for the shortlisted references and the
1.1 Exclusions
full papers of relevant material were obtained; disagreements
This guideline does not cover paediatric patients. An adden- in the final selections were resolved by discussion with the
dum to this guideline addressing the needs of paediatric entire GDG. In section 13.0, active interventions were assessed
patients with SJS/TEN is planned. The evidence for treatment only if studies recruited at least eight patients with SJS/TEN
of children differs from that of adult patients, and will be into the treatment group. The structure of the guidelines was
considered separately. then discussed, with headings and subheadings decided; dif-
The management of long-term sequelae of SJS/TEN is not ferent co-authors were allocated separate subsections. Each co-
considered in this document. author then performed a detailed appraisal of the selected lit-
erature, and all subsections were subsequently collated and
edited to produce the final guideline.
2.0 Stakeholder involvement and peer review
The guideline development group (GDG) consisted of consul-
4.0 Limitations of the guideline
tant dermatologists (D.C., S.A.W., H.Y.L., J.S., C.B.B., M.R.A.-
J., K.M.T.W., G.A.E.W., C.H.S.), including oral (J.S.) and uro- This document has been prepared on behalf of the BAD and is
genital specialists (S.A.W., C.B.B.), a histopathologist (M.P.), based on the best data available when the document was pre-
burns/plastic surgeon specialists (P.D., G.W., M.S.), a burns pared. It is recognized that under certain conditions it may be
anaesthestist (R.V.M.), intensive care specialists (A.V., R.V.M.), necessary to deviate from the guidelines and that the results of
an ophthalmologist (J.K.G.D.), a dermatological clinical nurse future studies may require some of the recommendations
specialist (D.B.) and a patient (P.W.). The draft document herein to be changed. Failure to adhere to these guidelines
went out for consultation to the BAD membership, British should not necessarily be considered negligent, nor should
Dermatological Nursing Group, Primary Care Dermatological adherence to these recommendations constitute a defence
Society, British Burn Association, British Association of Plastic, against a claim of negligence.
Reconstructive and Aesthetic Surgeons, Royal College of Oph-
thalmologists, Association of Anaesthetists of Great Britain and
5.0 Plans for guideline revision
Ireland, Intensive Care Society and SJS Awareness U.K. The
comments received were actively considered by the GDG. Fol- The proposed revision date for this set of recommendations is
lowing further review, the amended draft was recirculated to scheduled for 2021; where necessary, important interim
the stakeholders for comments and the finalized version peer- changes will be updated on the BAD website.
reviewed by the Clinical Standards Unit of the BAD (made up
of the Therapy & Guidelines Subcommittee) prior to publica-
6.0 Background
tion.
SJS and TEN are severe mucocutaneous reactions, usually to
drugs, characterized by blistering and epithelial sloughing.3
3.0 Methodology
The two terms describe phenotypes within a severity spec-
This set of guidelines has been developed using the BADs rec- trum, in which SJS is the less extensive and TEN the more
ommended methodology,1 and with reference to the Appraisal extensive form. The incidence of SJS/TEN is approximately 1
of Guidelines Research and Evaluation (AGREE II) instrument 2 cases per million per year.4,5 Although rare, SJS/TEN is a
(www.agreetrust.org).2 Recommendations were developed for devastating disease; in severe cases the acute phase may be
implementation in the National Health Service using a process accompanied by a variety of systemic complications, including
of considered judgement based on the evidence. A series of multiorgan failure. The mortality for SJS is < 10%, with the
specific questions was developed within the scope of the figure rising to 30% for TEN; overall SJS/TEN mortality is
guideline; for each question, PubMed, MEDLINE and Embase, about 22%.6 As well as carrying an appreciable mortality, sur-
and the Cochrane Library were searched for meta-analyses, vivors of the acute illness often develop significant long-term
randomized and nonrandomized controlled clinical trials, open sequelae.7
studies and case series to February 2016. The literature was SJS/TEN is characterized by widespread epithelial ker-
searched for evidence to address the questions. The search atinocyte apoptosis and necrosis, a process initiated by drug-
terms and strategies are detailed online (Data S1; see Support- induced cytotoxic T lymphocytes (CTLs).8 Major histocompat-
ing Information). Additional relevant references were also iso- ibility complex class I-restricted drug presentation leads to clo-
lated from citations in the reviewed literature, as well as nal expansion of CD8+ CTLs,9 which infiltrate the skin, while
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1196 Guidelines for SJS/TEN 2016, D. Creamer et al.
soluble factors induce keratinocyte apoptosis.10 Proapoptotic SJS/TEN, 97% developed erosive mucous membrane lesions;
molecules, including tumour necrosis factor (TNF)-a, inter- oral involvement was observed in 93% of patients, ocular in
feron (IFN)-c and inducible nitric oxide synthase, may link 78%, genital in 63% and all three sites in 66%.15 Respiratory
drug-induced immune responses to keratinocyte damage.11 tract epithelial necrolysis can occur, resulting in bronchial
Although soluble Fas ligand, perforin and granzyme have all obstruction and ventilatory compromise; necrolysis of gas-
been implicated in triggering keratinocyte programmed cell trointestinal epithelium leads to profuse diarrhoea. Owing to
death,12,13 current evidence favours granulysin as the key hypoperfusion and acute tubular necrosis, acute kidney injury
mediator of apoptosis in SJS/TEN.14 A study by Chung et al. may occur in the early phase of SJS/TEN. Mild elevation of
demonstrated the presence of high concentrations of secretory liver enzymes is common, but significant hepatic impairment
15-kDa granulysin in TEN blister fluid, while injection of 15- is rare.
kDa granulysin into mouse skin induces keratinocyte apopto- Despite the striking clinical presentation of SJS/TEN, a num-
sis, mimicking SJS/TEN.14 ber of disorders can present with blistering of the skin and
mucous membranes; the clinical differential diagnosis includes
pemphigus, pemphigoid, other immunobullous disorders and
7.0 Diagnosis, initial assessment, drug
erythema multiforme major (EMM) (see Table 1).
causality and prognosis in StevensJohnson
syndrome/toxic epidermal necrolysis
7.2 What are the recognized clinical phenotypes in
7.1 What are the clinical features of StevensJohnson StevensJohnson syndrome/toxic epidermal necrolysis?
syndrome/toxic epidermal necrolysis?
In a study by Bastuji-Garin et al.,16 a group of physicians expe-
SJS/TEN is an acute, severe dermatosis characterized by epi- rienced in managing SJS/TEN reviewed the clinical pho-
dermal loss and multisite mucositis, accompanied by systemic tographs of > 200 patients and categorized the cases
disturbance. A study by Revuz et al. of 87 consecutive patients according to type of cutaneous lesion and extent of maximal
managed in a specialist unit gives a detailed description of the epidermal detachment: (i) SJS [epidermal detachment < 10%
clinical features observed in SJS/TEN.15 In general, a pro- body surface area (BSA) plus widespread purpuric macules or
drome of fever, malaise and upper respiratory tract symptoms flat atypical targets]; (ii) overlap SJSTEN (detachment of 10
precedes the eruption by several days. Ocular inflammation 30% BSA plus widespread purpuric macules or flat atypical
may also develop before the skin signs. Cutaneous pain is a targets); (iii) TEN with spots (detachment > 30% BSA plus
prominent early feature in SJS/TEN, and the presence of this
symptom should alert the physician to incipient epidermal
necrolysis. Clinical observation in the series of Revuz et al.
demonstrated a wide variation in the type of lesion and degree
of skin involvement. The earliest lesions are atypical targets
and/or purpuric macules (Figs 1 and 2). Initial sites of
involvement are commonly the upper torso, proximal limbs
and face. Thereafter, lesions spread to involve the rest of the
trunk and distal limbs (Fig. 3). Involvement of the palms and
soles is often prominent (Fig. 4). Large areas of confluent ery-
thema develop in severe cases (Fig. 5). Lesional skin is tender
to touch; minimal shearing forces will cause the epidermis to
peel back (Fig. 6). This fragility is demonstrated by the Nikol-
sky sign, in which gentle lateral pressure causes lesional,
detachable epidermis (as opposed to detached epidermis) to
slide over the dermis. Although not specific for SJS/TEN (it is
also positive in pemphigus), the Nikolsky sign is a helpful
clinical indicator of epidermal necrolysis. Involved areas
expand and coalesce, reaching a maximum 57 days after dis-
ease onset. Blistering ensues in which necrotic epidermis sepa-
rates from underlying dermis, producing flaccid bullae
(Fig. 7). Extensive necrolysis results in the detachment of
sheets of epidermis, leaving areas of exposed dermis (Fig. 8).
Denuded dermis exudes serum, becomes secondarily infected
and readily bleeds. Involvement of the mucous membranes of Fig 1. Atypical targets. On the palm of this patient with Stevens
the eyes, mouth, nose and genitalia is usually an early feature Johnson syndrome/toxic epidermal necrolysis there are numerous
and leads to an erosive and haemorrhagic mucositis (Figs 9 circular lesions; most are characterized by a dark red centre
11). In the series described by Revuz et al. of 87 patients with surrounded by a pink ring. In some areas, the lesions are confluent.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1197
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1198 Guidelines for SJS/TEN 2016, D. Creamer et al.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1199
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1200 Guidelines for SJS/TEN 2016, D. Creamer et al.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1201
causing significant dysuria or retention. A urinary catheter will symptoms. Use multiple sources [including patient, relatives,
also permit accurate output monitoring to assist fluid replace- general practitioner (GP), pharmacist] to obtain a full drug his-
ment. tory.
Delineate a timeline for each drug, identifying the date
the drug was commenced and, when appropriate, discontin-
7.5 Is there a clinical method of determining drug
ued. Tools to facilitate timeline analysis include web-based
causality in StevensJohnson syndrome/toxic epidermal
freeware such as www.drugrash.co.uk. A latent period
necrolysis?
between the initial drug intake and onset of SJS/TEN always
SJS/TEN is primarily a drug-induced phenomenon, with a cul- occurs; 528 days following drug initiation is the most
prit drug being demonstrated in approximately 85% of likely period, unless there is a history of a previous reaction
cases.21 Identification of the causative agent may be straight- to the same drug, in which case the latency may be
forward in cases where a single drug is implicated, but diffi- shorter.
culties are posed by a patient who has been exposed to Estimate the probability that the drug was present in the
multiple drugs. Early withdrawal of the suspected agent is body at the onset of the reaction by taking into consideration
mandatory, as this decreases the risk of death.22 The patients pharmacokinetic parameters of the drug (e.g. half-life), any
other regular medicines should be continued. renal or hepatic dysfunction, and possible drug interactions,
Notoriety of specific drugs in causing SJS/TEN can be deter- which might lead to higher or lower levels of drug in the
mined from population pharmacovigilance data, which are body.
useful in identifying a likely culprit.6,2328 Two multinational For each drug taken by the patient, document any previous
casecontrol studies have evaluated drug causation risk: the exposures and any previous adverse reactions. Implication of a
first, conducted from 1989 to 1995, included 372 cases and particular medicine is more likely if the patient gives a past
1720 controls;23 the second, carried out between 1997 and history of a drug hypersensitivity reaction with the same or
2001, consisted of 379 cases and 1505 controls.6 From case similar drug.
control studies, a list of drugs that are strongly associated with For each drug taken by the patient, assess notoriety to cause
the induction of SJS/TEN has been drawn up; these medicines SJS/TEN (see Table 2).
are responsible for one-half of all cases (see Table 2). Parac- When a causative drug cannot be identified, consider other
etamol, aspirin, ibuprofen and corticosteroids have an unclear possible aetiological factors, such as mycoplasma infection.
association but are likely to be confounders used to treat pro-
dromal symptoms of SJS/TEN.
7.6 What is the value of prognostic scoring in Stevens
An algorithm, termed ALDEN (ALgorithm of Drug causality
Johnson syndrome/toxic epidermal necrolysis?
in Epidermal Necrolysis), has been developed to help define
drug causality in SJS/TEN.21 ALDEN is generally used as a tool In severe cases of SJS/TEN the acute systemic sequelae lead to
for retrospective assessment of drug causality, and not for use multiorgan failure and death. Papers investigating potential
in the acute phase of illness. However, the key parameters prognostic markers in SJS/TEN have identified several factors
described in ALDEN can be applied as a useful framework for associated with death, including delayed transfer to a specialist
determining drug culpability in clinical practice. unit, increasing patient age, increasing total BSA involvement,
presence of septicaemia and occurrence of granulocytope-
nia.29,30
7.5.1 Recommendations (strength of recommendation D;
In 2000 Bastuji-Garin et al. published a validated prognostic
level of evidence 3)
scoring system for SJS/TEN, called SCORTEN, which uses
List all medications (including OTC preparations) taken by the seven clinical parameters to predict probability of hospital
patient over a period of 2 months prior to the onset of mortality (see Tables 3 and 4).31 In SCORTEN, one point is
attributed to each of the seven parameters, with increasing
Table 2 Most common drugs causing StevensJohnson syndrome/ scores predicting higher mortality rates.
toxic epidermal necrolysis A longitudinal assessment of 144 patients demonstrated that
SCORTEN rises slightly during hospitalization, with a signifi-
Allopurinol cant difference between day 1 and day 4.32 Since the publica-
Carbamazepine
tion of the paper by Bastuji-Garin et al.,31 retrospective
Lamotrigine
Nevirapine
analysis of several SJS/TEN case series has confirmed SCOR-
Oxicam NSAIDs TENs ability to predict mortality accurately.3337
Phenobarbital
Phenytoin
Sulfamethoxazole and other sulfur antibiotics
7.6.1 Recommendation (strength of recommendation C;
Sulfasalazine level of evidence 2+)
NSAIDs, nonsteroidal anti-inflammatory drugs. SCORTEN should be calculated in all patients with SJS/TEN
within the first 24 h of admission.
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1202 Guidelines for SJS/TEN 2016, D. Creamer et al.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1203
use of an appropriate dressing on exposed dermis will reduce prophylactic systemic antibiotics may increase skin coloniza-
fluid and protein loss, limit microbial colonization and help tion, particularly with Candida albicans; therefore, antimicrobial
pain control. Covering the denuded skin may also accelerate therapy should only be instituted if there are clinical signs of
re-epithelialization. Once active blistering and epidermal infection.7 The SJS/TEN disease process may be accompanied
detachment ceases, re-epithelialization commences. Healing by a fever, which complicates detection of secondary sepsis;
may occur within a few days or may be protracted and take a therefore, patients should be monitored carefully for other
number of weeks to attain completion. signs of systemic infection such as confusion, hypotension,
A surgical approach involves debridement of detached epi- reduced urine output and reduced oxygen saturation.48 Cuta-
dermis to remove potentially infected material followed by neous infection may be accompanied by an increase in skin
physiological wound closure using biosynthetic dressings, pain. The detection of sepsis may also be indicated by a rise
xenograft or allograft.40,47 This more aggressive approach can in C-reactive protein and neutrophilia. If a monoculture of
be considered following failure of conservative management, organisms is detected on culture of swabs taken from multi-
characterized by clinical deterioration, extension of epidermal ple sites, which had previously showed mixed growth, this
detachment, local sepsis/subepidermal pus, delayed healing sign indicates that one particular strain of organism is
and wound conversion (the spontaneous progression of super- becoming predominant and increases the likelihood of inva-
ficial skin loss into a deeper cutaneous defect). sive infection.48 Consider activation of HSV in eroded or
Denuded dermis in SJS/TEN exudes serum and becomes vesicular areas that are slow to heal, particularly in genital
coated with necrotic debris. The exposed dermis and haem- and oral sites.
orrhagic crust act as a substrate for microbial colonization,
initially by Staphylococcus aureus and later by Gram-negative rods
8.2.1 Recommendations [strength of recommendation D
from the digestive flora, especially Pseudomonas aeruginosa.7 Cuta-
(good practice point); level of evidence 4]
neous infection will impair re-epithelialization and may lead
to systemic sepsis, which is the most common cause of The following general principles are applicable to all
death in SJS/TEN. Indiscriminate administration of patients with SJS/TEN and in all settings: (i) employ strict
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1204 Guidelines for SJS/TEN 2016, D. Creamer et al.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1205
peptic ulceration and limit translocation of gut bacteria. As be introduced, supplemented if required with oral opiate-
buccal mucositis in SJS/TEN often precludes normal oral based therapy such as codeine, or a synthetic opiate such as
intake, nasogastric feeding with a silicone tube should be tramadol. Nonsteroidal anti-inflammatory drugs should be
instituted when necessary. General principles of intensive care avoided because of the potential for renal and gastric injury.
nutrition are applicable and these are summarized in The If the pain score equates to moderate or severe pain then
European Society for Clinical Nutrition and Metabolism guide- prescribe regular opiate-based analgesia (e.g. morphine or fen-
lines.42,54 tanyl) delivered enterally, or by PCA, or via infusion. IV opi-
ates may be safely delivered in dedicated skin failure burn
centres or ICUs, with appropriate nursing levels. In patients
8.4.1 Recommendations (strength of recommendation C;
needing opiate-based analgesia, pain should be re-evaluated
level of evidence 3)
using the pain score on a 4-hourly basis and prior to any
Provide continuous enteral nutrition throughout the acute interventions. Involve the hospital acute pain team early.
phase of SJS/TEN, either by the oral route or via nasogastric Procedures such as dressing changes and bathing may
feeding if the former is precluded by buccal mucositis. require supplementary analgesia. EntonoxTM (50% nitrous
Deliver up to 2025 kcal kg 1 daily during the early, cata- oxide, 50% oxygen; BOC Healthcare, Manchester, U.K.) may
bolic phase of SJS/TEN. During the anabolic, recovery phase, be useful for this purpose when the area of cutaneous involve-
the aim should be to provide between 25 and 30 kcal kg 1 ment is small (< 10% BSA). Patients with significant areas of
daily. epidermal detachment will require additional pain relief for
procedures. Practitioners trained in sedation techniques should
deliver this in a safe, monitored environment, such as an ICU,
8.5 What analgesia is required in StevensJohnson
operating theatre or burn centre. Techniques to consider
syndrome/toxic epidermal necrolysis?
include target-controlled remifentanil infusions or bolus keta-
SJS/TEN is characterized by cutaneous pain, which is most mine-based analgo-sedation. Some patients may require gen-
severe at sites of epidermal detachment. There are no studies eral anaesthesia.
investigating different analgesic regimens in SJS/TEN. In the
absence of disease-specific evidence, patient comfort should be
8.6 What additional supportive medication is advisable
ensured using the principles of the World Health Organiza-
in a patient with StevensJohnson syndrome/toxic
tions analgesic ladder (www.who.int/cancer/pallia-
epidermal necrolysis?
tive/painladder/en/).55
Patients should receive adequate background simple analge- As in other critical care situations, patients with SJS/TEN are
sia to ensure comfort at rest, with the addition of opiates, as subject to stress-related gastric or duodenal ulceration and, if
required, delivered enterally, or by patient-controlled analgesia immobile, at risk of venous thromboembolism. Gastric protec-
(PCA), or via infusion. Involvement of the skin of the hands tion with a proton pump inhibitor is recommended, in the
by SJS/TEN may limit the ability of the patient to operate a minority in whom enteral nutrition cannot be established.57
PCA device. If the patient is in moderate-to-severe pain, which Prophylactic anticoagulation with low molecular weight hep-
is uncontrolled by simple analgesia, then an opiate-based regi- arin is necessary, unless contraindicated.
men using morphine should be initiated. Careful monitoring Anaemia and leucopenia are common complications of the
of level of consciousness, respiratory rate and oxygen satura- acute phase of SJS/TEN. Neutropenia will increase the risk of
tion is essential for safe delivery of opiate infusions. Addi- life-threatening sepsis and therefore administration of recom-
tional analgesia is often needed to address increased pain binant human G-CSF has been used to resist infectious compli-
associated with patient handling, repositioning, dressing cations.58 It has also been suggested that the use of G-CSF in
changes and physiotherapy.56 Intranasal diamorphine or sub- SJS/TEN may be immunomodulatory and enhance re-epithe-
lingual fentanyl can be useful for more limited procedures, lialization.58
unless extent of nose and mouth involvement precludes use of
these administration routes.
8.6.1 Recommendations (strength of recommendation C;
Adjuvants, including c-aminobutyric acid analogues, may
level of evidence 3)
have an opiate-sparing role. Topical anaesthesia of mucous
membranes may facilitate placement of nasogastric tubes and Patients with SJS/TEN who are immobile in bed should
urinary catheters. receive low molecular weight heparin as prophylactic antico-
agulation against venous thromboembolism.
During the acute phase of SJS/TEN, patients in whom ent-
8.5.1 Recommendations [strength of recommendation D
eral nutrition cannot be established may benefit from a proton
(good practice point); level of evidence 4]
pump inhibitor to protect against upper gastrointestinal stress
Use a patient-appropriate validated pain tool to assess pain in ulceration.
all conscious patients at least once a day.56 If the score is mild, Patients with SJS/TEN who are neutropenic may benefit
pain control with regular paracetamol (acetaminophen) should from the administration of recombinant human G-CSF.
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1206 Guidelines for SJS/TEN 2016, D. Creamer et al.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1207
at an unspecified time after the acute episode, were signifi- and should be used with caution in the presence of a corneal
cantly better in the group receiving topical corticosteroid com- epithelial defect.
pared with the lubricant group.66 Nonpreserved (as opposed to preserved) topical eye drops
are recommended; these are available in the U.K. for all the
preparations mentioned above.
9.1.1 Recommendations [strength of recommendation D
(good practice point); level of evidence 4]
9.2 Is systemic therapy effective in treating ocular
The eyes should be examined by an ophthalmologist as a part
involvement in StevensJohnson syndrome/toxic
of the initial assessment of a patient with SJS/TEN. Thereafter,
epidermal necrolysis?
daily ophthalmological review is necessary during the acute
illness. A direct ophthalmoscope to provide illumination, mag- Two studies have attempted to assess the efficacy of systemic
nification and a cobalt blue light source for fluorescein exami- therapy on ocular outcomes in SJS/TEN. A study by Araki et al.
nation is useful. Two-hourly application of a lubricant (e.g. reported five patients with acute ocular SJS/TEN receiving
nonpreserved hyaluronate or carmellose eye drops) should be pulsed IV methylprednisolone, followed by a tapering course
started immediately and continued through the acute illness. of oral prednisolone;67 there was no control group. Treatment
Ocular hygiene, to remove inflammatory debris and break was started at a mean of 1.2 days after SJS/TEN onset. At
down conjunctival adhesions, must be carried out each day by 12 months, the best-corrected visual acuity (VA) was 20/20
an ophthalmologist or ophthalmically trained nurse, and can or better; there was slight discomfort in 10/10 eyes, necessi-
be performed using saline irrigation, a squint hook and for- tating artificial tears; there was no evidence of epithelial
ceps. Scissors may be needed when adhesions are well devel- defects, neovascularization, opacification or keratinization.67
oped and cannot be removed with forceps alone. Blind In a retrospective case series from Yip et al. the ocular out-
sweeping of the fornices with a cotton bud or glass rod is not comes in eight patients with TEN treated with IV
recommended and may potentially cause damage. The applica- immunoglobulin (IVIg) were compared with a group of eight
tion of a topical local anaesthetic (e.g. proparacaine or tetra- historical controls, five of whom received oral prednisolone.68
caine) is necessary prior to the procedure. The patients in the IVIg-treated group were all survivors (pa-
In the unconscious patient, prevention of corneal exposure tients who died were excluded from study). A total of 25%
is essential to reduce the risk of ulceration and infection. (n = 2/8) of patients had mild eye involvement, 50% (n = 4/
Establishing a moisture chamber with polyethylene film 8) were moderately affected and 25% (n = 2/8) had severe
should be used to maintain corneal epithelial integrity. On eye involvement. All patients received 2 g kg1 IVIg over
healthy eyelid skin, paper tape can be used to affix the mois- 2 days. In total, 87% (n = 7/8) received oral prednisolone
ture chamber; care must be taken if there is sloughing of the prior to IVIg; 37% (n = 3/8) received a tapering course of
eyelid skin. All ICUs and burn centres should have corneal oral prednisolone after IVIg.68 The outcome measures were
exposure prophylaxis protocols in place. ocular complications and VA 6 weeks post-IVIg. There was no
Broad-spectrum topical antibiotic prophylaxis is recom- difference in severity of visually significant ocular complica-
mended by the authors in the presence of corneal fluorescein tions between the IVIg and control groups.68
staining or frank ulceration, when microbial keratitis has been A further retrospective paper describes the effect of systemic
excluded. The choice of antibiotic should be guided by local immunomodulatory treatment on ocular outcomes in 43
knowledge of antimicrobial resistance patterns, which vary patients from three centres treated with five systemic thera-
widely in different countries. In the U.K. a quinolone prepara- pies: steroids (n = 18), IVIg (n = 5), steroids with IVIg
tion is recommended, such as moxifloxacin or levofloxacin, (n = 14), systemic pulse steroids (n = 3) and supportive care
which has a wide range of activity against Gram-positive and only (n = 3). This paper concluded that the grading system
Gram-negative organisms, used four times daily. Other U.K. used had prognostic value for poor ocular outcomes but that
experts recommend conjunctival cultures on admission and their study could not demonstrate therapeutic benefit from the
prophylaxis guided by the sensitivity results. use of systemic immunomodulatory treatment to mitigate the
For suspected corneal infection, which may manifest as cor- ocular complications.62,63
neal stromal loss in the absence of an infiltrate, culture-guided When given in the acute phase of SJS/TEN, there is no
treatment is mandatory following initial hourly use of broad- robust evidence for the benefit of systemic corticosteroids or
spectrum topical antibiotic therapy, according to local proto- IVIg to improve ocular outcomes. Further studies are required
cols, and may be modified by microbial sensitivity results to establish the role of either intervention.
when these become available. Candida keratitis is relatively
common in patients with surface disease so that cultures for
9.3 Is the use of amniotic membrane transplantation
both bacteria and fungus are required.
effective in treating ocular involvement in Stevens
The use of topical corticosteroid drops (e.g. nonpreserved
Johnson syndrome/toxic epidermal necrolysis?
dexamethasone 0.1%), supervised by an ophthalmologist, may
reduce ocular surface damage in the acute phase of SJS/TEN. There are a number of published cases, and one casecontrol
Topical corticosteroids can mask the signs of corneal infection trial, reporting good ocular outcomes following amniotic
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1208 Guidelines for SJS/TEN 2016, D. Creamer et al.
membrane transplantation (AMT) during the acute phase of symblepharon ring, and performed at the bedside is a new,
SJS/TEN.6976 The suggested benefits of AMT include reduced promising, low-risk technique for delivering this therapy.
inflammation, enhanced re-epithelialization, reduction of scar-
ring and less symblepharon formation.6972 One case report of
10.0 Treatment of mouth involvement in
bilateral AMT suggests that early AMT may provide better out-
StevensJohnson syndrome/toxic epidermal
comes than later application.77 Cryopreserved amniotic mem-
necrolysis
brane (obtained from the National Health Service Blood and
Transplant Tissue Services, Liverpool, U.K.) is now available in Oral involvement in SJS/TEN is characterized by painful
a large (5 9 5 cm) size, as well as smaller sizes. The large mucosal erythema with subsequent blistering and ulceration.
size is ideal for lining the entire ocular surface. AMT may be Similar involvement of the vermillion of the lips progresses to
sutured onto the ocular surface, usually under general anaes- haemorrhagic sloughing with the development of dark adher-
thetic or deep sedation. The technique is described both by ent crusts. The tongue and palate are frequently affected,
Muqit et al. (using a procedure also favoured by the authors, while in severe cases, mucosal involvement may extend to the
incorporating absorbable sutures that do not require a further oropharynx, larynx, respiratory tract and oesophagus. Drinking
anaesthetic for removal)78 and by Gregory,70 who recom- and eating are usually severely compromised by oral involve-
mends a similar procedure, but incorporating nonabsorbable ment in acute SJS/TEN. If tolerated, ingested foods need to be
sutures and bolsters, which adds steps to the operation that soft, moist and low in acidity. However, fluids usually need
may be unnecessary. Videos are attached to both papers. For to be given intravenously and nutrition supplied via a soft,
sutured AMT the risks are low, without complications fine-bore nasogastric tube (see section 8.4).
reported in the available case series, and the procedure is not A long-term complication of acute oral involvement is labial
complex but time consuming. It takes about 90 min to per- and intraoral scarring, which may restrict mouth opening and
form on each eye, and is easier to carry out in an operating cause difficulty with eating or speaking.81 Sicca syndrome,
room under general anaesthesia, although, as with most oph- caused by damage to minor salivary glands, develops as a
thalmological procedures, it can be carried out under local chronic problem in up to 40% of patients.82
anaesthesia. After the procedure, a symblepharon ring or con-
former may be inserted. Symblepharon rings and conformers
10.1 Is topical therapy effective in treating oral
are available in the U.K. (Orbital Prosthetic Supplies, Crawley,
involvement in StevensJohnson syndrome/toxic
U.K.; www.orbitalprosthetic.com): their use and sizing has
epidermal necrolysis?
been described elsewhere.79 AMT performed at the bedside
under topical anaesthesia has been published in four reports Local measures for treating oral involvement in acute SJS/TEN
of eight SJS/TEN cases.7275 In these patients, amniotic mem- are supportive and empirical. Along with regular examination
brane was applied using a proprietary device and the tissue of the mouth and lips, attention should be given to regular
clipped into a plastic symblepharon ring (Prokera Bio-Tissue, emollients, topical analgesia and topical antiseptics. In an
Miami, FL, U.S.A.). uncontrolled series of patients with a variety of blistering con-
It is possible to retain large sheets of amniotic membrane in ditions affecting the mouth, including SJS/TEN, topical corti-
the conjunctival sac using symblepharon rings or conformers costeroids were shown to reduce oral inflammation.83 Topical
only.80 The procedure can be performed at the bedside rela- corticosteroids are widely prescribed in oral SJS/TEN, but
tively easily. A large retrospective study comparing the results there is limited directly applicable evidence for their use.
of AMT in 39 sutureless, and 36 sutured cases, demonstrated
better outcomes in sutureless than in sutured AMT.80
10.1.1 Recommendations [strength of recommendation D
A retrospective study from one unit compared 17 patients
(good practice point); level of evidence 4]
with SJS/TEN (33 eyes) receiving medical eye management,
with 13 patients (25 eyes) treated with AMT performed in the The mouth should be examined as a part of the initial assess-
acute phase of the disease.76 VA assessed within 3 months of ment of a patient with SJS/TEN. Thereafter, daily oral review
treatment demonstrated significantly better outcomes in the is necessary during the acute illness.
AMT group.76 Apply white soft paraffin ointment to the lips immediately,
and then every 2 h throughout the acute illness. Protect ulcer-
ated mucosal surfaces with a mucoprotectant mouthwash,
9.3.1 Recommendations (strength of recommendation D;
used three times a day (e.g. Gelclair; Alliance Pharmaceuti-
level of evidence 3)
cals, Chippenham, U.K.). Clean the mouth daily with warm
For patients in whom ocular hygiene is impossible without saline mouthwashes or an oral sponge, sweeping the sponge
general anaesthesia, and in those with extensive loss of ocular gently in the labial and buccal sulci to reduce the risk of fibro-
surface epithelia unresponsive to conservative measures, the tic scars.
use of AMT should be considered. It may improve outcomes Use an anti-inflammatory oral rinse or spray containing
if this procedure is carried out earlier rather than later in cases benzydamine hydrochloride every 3 h, particularly before eat-
with severe ocular surface ulceration. Sutureless AMT using a ing. If pain is inadequately controlled with benzydamine, then
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1209
a topical anaesthetic preparation, e.g. viscous lidocaine 2%, resolved, ultimately healing with scarring.85,86 In the long
15 mL per application, may be used as an alternative. Cocaine term, serious morbidity can ensue in the form of strictures
mouthwashes 2%5% can be used for severe oral discomfort and stenosis of the urethra, phimosis in males and vaginal
three times daily. synechiae in females, with resultant urinary and sexual dys-
Use an antiseptic oral rinse twice daily to reduce bacterial function.87
colonization of the mucosa. Agents available include 1.5%
hydrogen peroxide mouthwash (e.g. Peroxyl mouthwash,
11.1 Is topical therapy effective in treating urogenital
10 mL twice daily; Colgate, New York, NY, U.S.A.) or 0.2%
involvement in StevensJohnson syndrome/toxic
chlorhexidine digluconate mouthwash (e.g. Corsodyl mouth-
epidermal necrolysis?
wash, 10 mL twice daily; GSK, Brentford, U.K.). Diluting
0.2% chlorhexidine mouthwash by up to 50% will reduce the Local measures for treating urogenital involvement in acute
soreness that can accompany this treatment. SJS/TEN are supportive and empirical. Along with regular
Oral and lip swabs should be taken regularly if bacterial or examination of the urogenital tract, attention should be given
candidal secondary infection is suspected. Candidal infection to regular emollient, appropriate dressings and topical antimi-
should be treated with nystatin oral suspension 100 000 units crobial treatment. Topical corticosteroids may be useful to
four times daily for 1 week, or miconazole oral gel (e.g. Dak- reduce urogenital inflammation.88,89
tarin oral gel; Johnson & Johnson, New Brunswick, NJ,
U.S.A.) 510 mL held in the mouth after food four times
11.1.1 Recommendations [strength of recommendation D
daily for 1 week. Slow healing of the oral mucosa may reflect
(good practice point); level of evidence 4]
secondary infection by, or reactivation of, HSV.
Consider using a topical corticosteroid four times daily (e.g. Examine the urogenital tract as a part of the initial assessment
betamethasone sodium phosphate 0.5 mg in 10 mL water as a of a patient with SJS/TEN. In women, early assessment by a
3-min rinse-and-spit preparation). A more potent preparation, vulval specialist is recommended for consideration of dilators
clobetasol propionate 0.05%, mixed in equal amounts with to prevent vaginal synechiae. Speculum examination needs to
Orabase (Colgate), can be applied directly to the sulci, labial be undertaken with plastic speculums so that all vaginal walls
or buccal mucosae daily during the acute phase. can be fully assessed. Uncircumcised male patients should be
checked for preputial retractability. Thereafter, daily docu-
mented urogenital review is necessary during the acute illness.
10.2 Is systemic therapy effective in treating oral
Apply white soft paraffin ointment to the urogenital skin
involvement in StevensJohnson syndrome/toxic
and mucosae immediately and thereafter every 4 h through
epidermal necrolysis?
the acute illness.
There are no controlled trials of systemic corticosteroid in the Use MepitelTM (M olnlycke Health Care) dressings to eroded
management of mouth involvement in SJS/TEN; however, ster- areas in the vulva and vagina to reduce pain and prevent adhe-
oids are commonly used by oral physicians in severe EMM. In sions. A dilator or tampon wrapped in Mepitel should be
a series comprising eight EMM cases and four cases of SJS, inserted into the vagina to prevent formation of synechiae.
patients were treated with fluocinolone, prednisolone or Consider applying a potent topical corticosteroid ointment
methylprednisolone in a variety of doses for 57 days during once daily to the involved, noneroded, urogenital surfaces.
the acute illness.84 Oral assessment revealed a complete remis- Catheterize all patients to prevent strictures forming in the
sion of buccal lesions in all patients 710 days after onset of urethra.
systemic corticosteroid treatment.84 Nonetheless, there is cur-
rently insufficient evidence to recommend systemic corticos-
11.2 Is systemic therapy effective in treating urogenital
teroids for the treatment of the oral manifestations of acute
involvement in StevensJohnson syndrome/toxic
SJS/TEN. There are no published studies of oral outcomes in
epidermal necrolysis?
acute SJS/TEN treated with systemic ciclosporin or IVIg.
There are no published studies of urogenital outcomes in
patients with acute SJS/TEN treated with systemic corticos-
11.0 Treatment of urogenital involvement in
teroids, ciclosporin or IVIg.
StevensJohnson syndrome/toxic epidermal
necrolysis
12.0 Treatment of airway involvement in
Involvement of the urogenital tract in SJS/TEN is characterized
StevensJohnson syndrome/toxic epidermal
by mucosal erythema, blistering and erosions. During the
necrolysis
acute phase pain is prominent and urinary dysfunction (dy-
suria or retention) is common. Secondary infection by bacteria Pulmonary complications are an underappreciated manifesta-
or candida is a frequent complication of urogenital involve- tion of SJS/TEN, and may be a marker of disease severity and
ment. HSV activation may also occur. Erosions of the genital mortality. Respiratory tract involvement does not seem to cor-
mucosae may persist for many weeks after the acute phase has relate with the extent of epidermal detachment.
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1210 Guidelines for SJS/TEN 2016, D. Creamer et al.
A single-centre, prospective study characterized airway trial has been conducted in TEN: the anti-TNF agent thalido-
involvement in SJS/TEN into three groups based on whether mide was compared with placebo; however, the study was
hypoxaemia and respiratory symptoms were present, and the discontinued prematurely because of an excess of deaths in
time course of the development of hypoxaemia.90 Patients the thalidomide treatment group.92
without hypoxaemia during the acute phase (group 1) suf- The immunological basis for SJS/TEN has led physicians to
fered no pulmonary complications or sequelae, and had low prescribe immunomodulating drugs, several of which have
mortality.90 One-quarter of patients presented with early pul- been studied in uncontrolled series. In this guideline, active
monary manifestations (group 2) characterized by dyspnoea interventions were assessed if studies recruited at least eight
and an increased respiratory rate chest radiographs were typ- patients with SJS/TEN into the treatment group. Of all active
ically normal on admission, with later diffuse pulmonary infil- interventions (excluding thalidomide) only three drugs ful-
trates.90 Bronchial hypersecretion occurred in 70% of these filled the inclusion criteria: IVIg, systemic corticosteroid and
patients, and fibreoptic bronchoscopy revealed a pattern of ciclosporin.
diffuse loss of bronchial epithelium in the proximal airways,
with evolving epithelial detachment caused by epithelial
13.1 Is treatment with intravenous immunoglobulin
necrosis. There was no evidence of airway infection in this
effective in StevensJohnson syndrome/toxic epidermal
group, and normal bronchial mucosa began to recover at the
necrolysis?
same time as skin recovery in survivors. Mechanical ventilation
was required in 90% of cases, and a high mortality rate Evidence for possible efficacy of IVIg in SJS/TEN came from a
(70%) was reported. In patients with bronchial epithelial study indicating a role for FasFas ligand (FasFasL) interac-
necrolysis, airway sloughing may occur, and can cause sudden tion in TEN keratinocyte apoptosis.12 This study demonstrated
airway obstruction and death (De Prost, personal communica- that high concentrations of normal immunoglobulin inhibited
tion). A small percentage of patients with early pulmonary FasFasL interaction and apoptosis through anti-Fas activity.
manifestations go on to develop chronic respiratory problems, The authors then reported an uncontrolled, prospective open
which include bronchiolitis obliterans, bronchiectasis and trial of 10 patients with TEN treated with IVIg, none of whom
chronic bronchitis. The prognosis is poor, with a mortality died.12 As per the 1998 report of Viard et al.,12 a further 16
rate of approximately 40%.91 Delayed pulmonary manifesta- studies of IVIg treatment in SJS/TEN met the inclusion criteria
tions (group 3) occurred in 19% of cases and consisted of a for assessment (data summarized in Table 7).28,34,46,93105 Of
heterogeneous group of conditions, including atelectasis, bac- the 17 studies identified, 11 are retrospective cohort studies
terial pneumonia and fluid overload.90 Biopsy confirmed the and six are prospective. Pooling the results yields a total of
absence of pulmonary epithelial detachment in these patients; 374 SJS/TEN receiving IVIg; however, one study contained
there was no requirement for ventilation in this group, and all patients reported in previously published series;95 thus, the
patients recovered.90 total number of patients is lower. In all studies the primary
outcome measure is mortality. In a systemic review and meta-
analysis, published in 2012 by Huang et al. (all studies of at
12.1 Recommendations [strength of recommendation D
least eight patients with SJS/TEN receiving IVIg),106 a pooled
(good practice point); level of evidence 4]
estimate of mortality risk was determined, comparing IVIg
Respiratory symptoms and hypoxaemia on admission should and supportive care in patients with TEN and SJSTEN overlap.
prompt urgent discussion with an intensivist and rapid transfer Statistical analysis was also performed on the raw data to com-
to the ICU or burn centre, as deterioration requiring mechani- pare the clinical differences between high- and low-dose treat-
cal ventilation is likely. Relatives should be counselled as to ment in adult patients, and between paediatric and adult
the prognostic significance of this development. patients treated with IVIg. The overall mortality rate of 221
Fibreoptic bronchoscopy should be undertaken to identify patients with TEN and SJSTEN overlap (patients with SJS
bronchial involvement, evaluate prognosis and investigate the were not included) treated with IVIg was 19.9%. The pooled
presence of pneumonitis by bacterial sampling. Bronchoscopy odds ratio (OR) for mortality from six observational con-
may have a role in preventing atelectasis and airway obstruc- trolled studies comparing IVIg and supportive care was 1.00
tion by allowing the mechanical removal of sloughed bron- [95% confidence interval (CI) 0.581.75; P = 0.99].106 Paedi-
chial epithelium. atric patients treated with IVIg had significantly lower mortal-
Patients with ongoing respiratory symptoms should be clo- ity than adults (0% vs. 21.6%, respectively; P = 0.01). Adults
sely monitored with pulmonary function testing and high- treated with high-dose IVIg exhibited significantly lower mor-
resolution computed tomography scanning. tality than those treated with low-dose IVIg (18.9% vs. 50%,
respectively; P = 0.02); however, multivariate logistic regres-
sion model adjustment indicated that IVIg dose does not cor-
13.0 Active therapy in StevensJohnson
relate with mortality (high-dose vs. low-dose OR 0.494, 95%
syndrome/toxic epidermal necrolysis
CI 0.1062.300; P = 0.37).104 However, these findings should
Currently, no active therapeutic regimen with unequivocal be interpreted with caution given the major methodological
benefit exists for SJS/TEN. Only one randomized controlled limitations of the original cohorts. Since the publication of the
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Table 7 Summary of intravenous immunoglobulin (IVIg) studies in StevensJohnson syndrome (SJS)/toxic epidermal necrolysis (TEN)
Campione et al. Single Retrospective case TEN (10) 2 g kg 1 given over 1/10 (10%) SCORTEN-predicted Effective 3
(2003)97 dermatology unit series with 5 days mortality 3.5/10
SCORTEN-predicted (35%)
mortality as
comparator
Prins et al. Multiple centres Retrospective; case Overlap Mean 0.7 g kg 1 6/48 (12%) NA Effective 3 Duplicated cases
(2003)95 series SJS/TEN (7) daily for 4 days from Viard et al.
(including TEN (41) (1998),12 Campione
previously et al. (2003)97 and
reported cases, from Trent et al. (2003)94
three
other studies);
noncontrolled
Trent et al. Single Retrospective case SJSTEN 1 g kg 1 daily for 1/16 (6%) SCORTEN-predicted Effective 3
(2003)94 dermatology unit series with overlap (6) 4 days (n = 15); mortality 5.81/16
SCORTEN-predicted TEN (10) 0.4 g kg 1 daily for (36%)
mortality as 4 days (n = 1)
comparator
1
Al-Mutairi et al. Single Retrospective, TEN (12) 0.51.0 g kg for 0/11 (0%) NA Effective 3
(2004)98 dermatology unit noncontrolled 45 days
(continued)
1
Gravante et al. Burns unit Retrospective; case SJS (1) 0.4 g kg daily for 7/17 (41%) No comparator group Effective 3
(2007)102 series TEN (16) 5 days or SCORTEN-
predicted mortality
given
Stella et al. Burns unit Retrospective case IVIg group: 0.7 g kg 1 daily for 6/23 (26%) SCORTEN-predicted Effective 3 This series included
(2007)46 control SJS (2); 4 days + mortality 8.2/23 nine cases published
series; control SJS/TEN methylprednisolone (36%) in Stella et al.
group supportive overlap 250 mg daily for (2001).93 Control
care only (16); TEN (5) 2 days group TBSA
involvement
significantly lower
in IVIg group
compared with
controls
Control
group:
TEN (8)
(continued)
Aihara et al. Multiple Prospective; case SJS (5) 400 mg kg 1 daily 0/8 (0%); 7/8 None Effective 3 Co-treatment of all
(2015)105 dermatology series; TEN (3) IVIg for 5 patients classed patients with
centres no comparator consecutive days in as responders corticosteroid
group conjunction with according to a variable dosing.
systemic severity-of-illness Only 8/41 cases
corticosteroid score designed included in the final
therapy (variable by the authors report reporting
dose) bias
NA, not applicable; HDU, high-dependency unit; TBSA, total body surface area. aSee Appendix 1.
meta-analysis by Huang et al.,106 a further study by Firoz et al., This group was compared with six historical SJS/TEN con-
which included 23 patients with TEN treated with IVIg, trols treated with systemic corticosteroids.115 There was a
demonstrated no improved survival in patients receiving IVIg significantly enhanced speed of epithelialization and reduced
vs. supportive care alone.103 In 2013, Lee et al. published a length of hospital stay in the ciclosporin group.115 Compar-
retrospective analysis of 64 patients with SJSTEN overlap or ison of SCORTEN-predicted mortality demonstrated a benefit
TEN treated with IVIg at a single specialized referral centre in of ciclosporin over corticosteroids.115 Kirchhof et al. pub-
Singapore.104 The mortality in their patients, when compared lished a retrospective review from a single centre of 64
with predicted outcome from SCORTEN, showed no benefit patients with SJS/TEN receiving either ciclosporin or IVIg
from IVIg.104 In addition, when stratified according to dosage, (doses of each varied).116 Analysis of predicted SCORTEN
there was no mortality difference between patients who mortality compared with actual mortality indicated a relative
received high-dose (> 3 g kg 1) vs. low-dose (< 3 g kg 1) mortality benefit for the use of ciclosporin [standardized
IVIg.104 mortality ratio (SMR) 0.43] vs. IVIg (SMR 1.43).116 Data
from the ciclosporin studies are summarized in Table 9.
Sources of potential bias are indicated in the table.
13.2 Is treatment with systemic corticosteroid effective in
StevensJohnson syndrome/toxic epidermal necrolysis?
13.4 Other treatments used in the management of
Corticosteroids have been used in the management of SJS/TEN
StevensJohnson syndrome/toxic epidermal necrolysis
for many years. Proponents emphasize the importance of
high-dose corticosteroid given early in the disease course to Other therapies have been tried in SJS/TEN, but studies con-
inhibit inflammation; opponents suggest that systemic corti- tain small numbers of patients and are, generally, uncon-
costeroids increase the risk of sepsis. Ten published studies of trolled. Plasmapheresis has been used in SJS/TEN that is
corticosteroid treatment in SJS/TEN met the inclusion criteria refractory to treatment; reports suggest that this therapeutic
for assessment: all are case series, none are randomized con- modality may provide a rapid benefit.117,118 The bioregenera-
trolled trials and most are retrospective.2830,34,107111 Retro- tory and immunomodulatory properties of G-CSF have led
spective analysis of the EuroSCAR data indicated a lower some to claim efficacy (that transcends the management of
mortality in German patients (but not French patients) treated leucopenia) in the active treatment of TEN by arresting the
with corticosteroids compared with controls receiving sup- hypersensitivity and stimulating re-epithelialization.58 More
portive care alone.28 Two studies investigated the effects of recently there has been interest in a therapeutic role for TNF-
pulsed IV high-dose corticosteroids.107,112 In the study by a inhibitors. Paradisi et al. reported a series of 10 patients with
Kardaun and Jonkman,107 12 patients received 100 mg or SJS/TEN treated with a single 50-mg subcutaneous dose of
1.5 mg kg1 of IV dexamethasone for 3 days and were etanercept. There was no control group. All patients responded
reported to have a decreased mortality compared with SCOR- with a mean re-epithelialization time of 8.5 days. None of the
TEN. Hirahara et al. presented a series of eight patients with patients died, despite a mean SCORTEN-predicted mortality
SJS/TEN who received 1000 mg of IV methylprednisolone on rate of about 50%.119
three consecutive days, followed by either a tapering course
of oral prednisolone or a further 2 days of half-dose IV
13.5 Evidence synthesis
methylprednisolone.112 No patients died despite a SCORTEN-
predicted mortality of 1.6.112 Data from the corticosteroid The GDG found interpretation of the reviewed studies chal-
studies are summarized in Table 8. Sources of potential bias lenging, given major ascertainment bias in reported cohorts,
are indicated in the table. low numbers of patients, variation in the timing and nature of
intervention, case mix and setting, and quality of supportive
care. The GDG did not consider any of the data presented of
13.3 Is treatment with ciclosporin effective in Stevens
sufficient quality or consistency to make specific recommenda-
Johnson syndrome/toxic epidermal necrolysis?
tions either for or against the use of active interventions, and
Effective inhibition of lymphocyte function identifies ciclos- highlighted the need for future research (see section 16.0). It
porin as a drug with theoretical benefit in SJS/TEN. Four cohort was noted that there is a lack of consensus even among clini-
studies of ciclosporin treatment in SJS/TEN meet the inclusion cians with experience in managing SJS/TEN, with, for exam-
criteria for assessment (summarized in Table 9).113116 A study ple, strong advocates for use and avoidance of IVIg.
by Valeyrie-Allanore et al. from the dermatology intensive Withdrawal of culprit drug and meticulous attention to
therapy unit in Creteil, Paris, demonstrated that in 29 high-quality, multidisciplinary supportive care is the priority.
patients with SJS/TEN ciclosporin given at a dose of
3 mg kg 1 daily for 10 days, and thereafter tapered, was
13.6 Recommendations (strength of recommendation D;
effective.114 There were no deaths, despite a SCORTEN pre-
level of evidence 4)
dicted mortality of 2.75/29.114 Singh et al. reported 11
patients with SJS/TEN treated with ciclosporin 3 mg kg 1 There is no conclusive evidence to demonstrate the benefit of
daily for 7 days, and then tapered over a further 7 days. any one intervention over conservative management nor
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Table 8 Summary of corticosteroid studies in StevensJohnson syndrome/toxic epidermal necrolysis (SJS/TEN)
Reported Level of
Study Setting Design Patients (n) Intervention Outcome: mortality Comparator benefit evidencea Additional notes
Murphy Single burn Retrospective; TEN (12) Highly variable doses 8/12 NA No comment 3 Timing, duration
et al. centre case series; received, no details about made by and dose of
(1997)111 noncontrolled specific dosing authors corticosteroid
therapy highly
variable
Schulz Single burn Retrospective; TEN (34) No details about 13/34 NA Ineffective 3 No evidence of
et al. centre case series; corticosteroid dosing case validation;
(continued)
Reported Level of
Study Setting Design Patients (n) Intervention Outcome: mortality Comparator benefit evidencea Additional notes
Kardaun and Single Retrospective; SJS (1) First four patients: IV 1/12 SCORTEN- Effective 3 Case validation
Jonkman dermatology case series; SJSTEN dexamethasome 100 mg predicted unclear. Change
(2007)107 centre noncontrolled overlap (4) once daily for 3 days + mortality: 4/12 of treatment
TEN (7) 500 mg protocol during
cyclophosphamide. series
Subsequent patients:
1.5 mg kg1 IV
dexamethasone for 3 days
Schneck Multiple Retrospective; SJS (57) Maximum steroid dose 21/119 Mortality Ineffective (on 2 Robust case
et al. centres in case series; SJSTEN 250 mg prednisolone expressed as multivariate validation.
(2008)28 Germany and noncontrolled overlap (44) equivalent (IQR 100 OR: corticosteroids analysis) Steroid group
France TEN (18) 500 mg). Given for compared with had less severe
1216 Guidelines for SJS/TEN 2016, D. Creamer et al.
Yang et al. Single Retrospective; SJS (10) and 11.5 mg kg 1 daily 10/45 (10 TEN) SCORTEN- Corticosteroid 2 Case validation
(2009)109 dermatology case series; TEN (35) in methylprednisolone or in corticosteroid predicted alone ineffective, unclear.
centre noncontrolled corticosteroid equivalent (details not group; 3/20 mortality 8.63 in IVIg/corticosteroid Insufficient
arm (n = 45) given); IVIg 0.4 g kg 1 (two TEN and corticosteroid may confer benefit detail on
SJS (8) and day for 5 days one SJS) in IVIg/ group; 3.51 in IVIg/ (nonsignificant corticosteroid
TEN (12) corticosteroid group corticosteroid difference) dosing
in IVIg/ group
corticosteroid
arm (n = 20)
(continued)
Results suggesting
Patients in IVIg/
varied according
of corticosteroid
Subsequent doses
Additional notes
reach statistical
benefit did not
involvement at
teroids or ciclosporin in the context of SJS/TEN. The GDG
corticosteroid
higher TBSA
significance.
to response
group had
considers that, ideally, such interventions should be practised
NA, not applicable; BSA, body surface area; IV, intravenous; IQR, interquartile range; OR, odds ratio; CI, confidence interval; IVIg, intravenous immunoglobulin; TBSA, total BSA. aSee Appendix 1.
baseline
under the supervision of a specialist skin failure MDT in the
context of a clinical study or a case registry.
evidencea
Level of
3
As the patient recovers from the mucocutaneous and systemic
manifestations of acute SJS/TEN, preparations can be made for
discharge. Before leaving the hospital, information on the cul-
prit drug should be relayed to the patient. The drug allergy
Reported
Effective
benefit
SCORTEN-predicted
corticosteroid group
TEN and specify the patients follow-up plan (see Appendix 2).
NICE guidance suggests that severe nonimmediate cutaneous
reactions are referred to a specialist drug allergy service for
expert review, which in the context of SJS/TEN is likely to be
0/8
corticosteroid
TEN (15) in
overlap (2)
SJS (9) and
SJS (43) and
TEN (15)
only arm
(n = 58)
(n = 24)
TEN (3)
in IVIg/
SJSTEN
SJS (3)
noncontrolled
Retrospective;
Retrospective;
case series;
case series;
dermatology
centre
Setting
Single
Table 8 (continued)
drug(s).
At discharge, refer the patient to local social services, when
(2010)110
(2013)112
et al.
Study
Chen
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
Table 9 Summary of ciclosporin (CsA) studies in StevensJohnson syndrome/toxic epidermal necrolysis (SJS/TEN)
Singh et al. Dermatology Casecontrol study SJS (5) CsA 3 mg kg 1 daily 0/11 SCORTEN-predicted Yes 3 No evidence of case
(2013)115 unit (historical controls) SJSTEN for 7 days, and mortality in control validation
overlap (3) tapered for 7 days group treated with
TEN (3) corticosteroid
Kirchhof et al. Dermatology Retrospective series: SJSTEN Various doses of CsA CsA SMR CsA-treated group Yes 3 No evidence of case
(2014)116 unit CsA vs. IVIg overlap (64) and IVIg 0.43; IVIg compared with validation. No control
SMR 1.43 IVIg-treated group group
BSA, body surface area; ICU, intensive care unit; IVIg, intravenous immunoglobulin; SMR, standardized mortality ratio. aSee Appendix 1.
Encourage the patient to wear a MedicAlert bracelet or amu- this series patch testing showed positive reactions in 0%
let bearing the name of the culprit drug. (n = 0/5) of cases of carbamazepine-induced SJS/TEN.126
The drug allergy should be documented in the patients
notes. All doctors involved in the patients care, especially the
15.2 What is the evidence that in vitro tests can identify
GP, should be informed about the drug allergy episode and
a culprit drug in StevensJohnson syndrome/toxic
the culprit.
epidermal necrolysis?
Warn the patient to avoid OTC medications where precise
constituents are unclear. The method of isolation of peripheral blood mononuclear cells
Report episodes of drug-induced SJS/TEN to the national (PBMC) followed by in vitro challenge with the putative causal
pharmacovigilance authorities (the MHRAs Yellow Card drug has been widely studied in the context of drug hypersen-
Scheme in the U.K., www.yellowcard.mhra.gov.uk). sitivity testing. Although these assays involve the culture of
If the patient had eye involvement during the acute phase, PBMC with the drug in question, it is generally accepted that
organize an outpatient clinic appointment with an ophthal- the responding cells are T lymphocytes.
mologist within a few weeks of discharge.
Organize an outpatient clinic appointment in dermatology
15.2.1 Lymphocyte transformation tests (lymphocyte
or burns plastic surgery within a few weeks of discharge.
proliferation assay)
Patients need to be monitored for complications in skin,
mouth, urogenital tract, respiratory and gastrointestinal sys- Lymphocyte proliferation, as measured by uptake of 3H-thy-
tems. Psychological evaluation and support should be consid- midine in dividing cells, is widely referred to as the lympho-
ered. cyte transformation test (LTT). However, variations in
standard methodology mean that comparative interpretation is
difficult. Overall, the number of reports specifically character-
15.0 Drug hypersensitivity tests in Stevens
izing the value of LTT for SJS/TEN is low. Studies have
Johnson syndrome/toxic epidermal necrolysis
reported positive LTT responses in 100% (n = 4/4) of SJS
Once a diagnosis of drug-induced SJS/TEN has been made, cases to a variety of culprit drugs,127 and 75% (n = 3/4) of
investigations may be helpful in confirming or identifying SJS cases, again triggered by a range of medicines.128 How-
the culprit medication. As T-cell-mediated mechanisms pre- ever, neither of these reports compared drug LTT assays in a
dominate in SJS/TEN, assays for drug-specific IgE-mediated control population. A study by Kano et al. showed that in two
immediate reactions (i.e. skin-prick testing and specific IgE cases of SJS, LTT results were positive in the acute phase of
testing) are of no value. Appropriate tests are those that the reaction but weakened over 2 months.129 A report by
identify delayed type IV hypersensitivity reactions, most Tang et al. suggested that LTT was not of value for the investi-
notably drug patch testing and in vitro assays, such as drug- gation of lamotrigine-induced SJS/TEN as only 21% (n = 3/
induced T-cell proliferation (lymphocyte transformation tests) 14) cases showed a positive result.130
and drug-induced lymphocyte cytokine production. Oral A study by Roujeau et al. reported 11 cases tested with LTT
provocation studies are not ethical in SJS/TEN because of a within 1 month of recovery from TEN.131 Although 44% of
risk of life-threatening reactions. Although a lesser risk, cases showed positive LTTs to the culprit drug, control groups
induction of severe reactions has been recorded with patch also showed a similar frequency of positive drug LTT
testing. assays.131 The authors concluded that the assay is not useful in
cases of TEN. However, other series have shown positive
results in only 15% and 0% (n = 0/18) of controls.132,133 In
15.1 What is the evidence that patch tests can identify a
the series by Polak et al.,134 55% (n = 5/9) of EMM/SJS/TEN
culprit drug in StevensJohnson syndrome/toxic
cases demonstrated positive LTTs in the context of a low false-
epidermal necrolysis?
positive rate of 4.9%, while another series showed the LTT to
Reviews have commented on the value of patch testing in be positive in only 27% (n = 4/15) of cases.133 Lymphocyte
drug allergy and have suggested explanations for the variable proliferation measured by other techniques such as the car-
sensitivity and specificity of this assay in different reaction pat- boxyfluorescein succinimidyl ester dilution assay has not been
terns and with different drugs.123 A study by Wolkenstein widely examined in SJS/TEN. A recent report has suggested
et al. patch tested 22 cases of SJS/TEN (series n = 59) and that blockade of inhibitory molecules to T-cell proliferation
found only 9% (n = 2/22) of the cases to be positive.124 during the LTT assay (with anticytotoxic T-lymphocyte-asso-
Another study by Lin et al. demonstrated positive patch tests to ciated protein 4 and antiprogrammed death-ligand 1), may
carbamazepine in 62% (n = 10/16) of cases of carba- increase positivity from 32% to 50%.135
mazepine-induced SJS/TEN compared with 0% (n = 0/10) of
controls.125 In this study, cross-reactivity to other aromatic
15.2.2 Lymphocyte function assays
anticonvulsant drugs was observed.125 A recent French multi-
centre study reported 17 patients with SJS/TEN where positive Drug-induced lymphocyte production of cytokines or other
patch tests were identified in 23% (n = 4/17) of cases, but in mediators measured by enzyme-linked immunosorbent assay,
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1220 Guidelines for SJS/TEN 2016, D. Creamer et al.
Table 10 Summary
Initial assessment Take a detailed history from the patient and/or relatives
on presentation Perform a full physical examination, including baseline body weight, and record the vital signs, including oxygen
saturation
Order a set of investigations: FBC, U&E, LFT, glucose, magnesium, phosphate, bicarbonate, mycoplasma serology,
CXR, skin biopsy
Initiate a primary management plan: (i) establish peripheral venous access; (ii) if patient cannot maintain adequate
nutrition orally, insert a nasogastric tube and institute nasogastric feeding; (iii) insert a urinary catheter if
urogenital involvement is causing significant dysuria/retention
Strength of recommendation D (GPP)
Determination of Identify causative agent and withdraw immediately
drug causality Strength of recommendation D
Prognostic scoring Calculate SCORTEN within the first 24 h
Strength of recommendation C
Care setting An MDT should be convened, coordinated by a specialist in skin failure, usually dermatology and/or plastic
surgery, and including clinicians from intensive care, ophthalmology and skincare nursing
Patients with > 10% BSA epidermal loss should be admitted without delay to a burn centre or ICU with
experience of treating patients with SJS/TEN and facilities to manage the logistics of extensive skin loss wound
care
Patients must be barrier-nursed in a side room controlled for humidity, on a pressure-relieving mattress with the
ambient temperature raised to between 25 C and 28 C
Strength of recommendation D (GPP)
Skin management Employ strict barrier nursing to reduce nosocomial infections
regimen 1 Take swabs for bacterial and candidal culture from three areas of lesional skin, particularly sloughy or crusted
(applicable to all areas, on alternate days throughout the acute phase
patients in all Administer systemic antibiotics only if there are clinical signs of infection
settings) Strength of recommendation D (GPP)
Skin management Institute a conservative approach in all patients as follows:
regimen 2 (this Regularly cleanse wounds and intact skin by irrigating gently using warmed sterile water, saline or an
may involve a antimicrobial
conservative such as chlorhexidine (1/5000)
and/or surgical Apply a greasy emollient, such as 50% white soft paraffin with 50% liquid paraffin, over the whole epidermis,
approach based including denuded areas
on the specialist Apply a topical antimicrobial agent to sloughy areas only (choice should be guided by local microbiological
MDTs daily advice). Consider silver-containing products/dressings
review of the The detached, lesional epidermis may be left in situ to act as a biological dressing. Blisters should be decompressed
individual needs by piercing and expression or aspiration of tissue fluid
of the patient) Apply nonadherent dressings to denuded dermis [suitable dressings include MepitelTM (M olnlycke Health Care,
Dunstable, U.K.) or TelfaTM (Covidien, Mansfield, MA, U.S.A.)]
A secondary foam or burn dressing should be used to collect exudate [suitable dressings include Exu-Dry (Smith
& Nephew, London, U.K.)]
Consider transfer to a Burn Centre in patients with TEN (> 30% BSA epidermal loss) and evidence of the
following:
clinical deterioration, extension of epidermal detachment, subepidermal pus, local sepsis, wound conversion and/
or delayed healing. In a burn centre, conservative measures may be supplemented with a surgical approach:
Remove necrotic/loose infected epidermis and clean wounds using a topical antimicrobial agent (e.g. betadine or
chlorhexidine) under general anaesthetic
Consider debridement with VersajetTM (Drytac, Bristol, U.K.)
Physiological closure with Biobrane/allograft/xenograft skin in patients with early presentation involving
noninfected and large confluent areas
Strength of recommendation D (GPP)
Fluid replacement Site venous lines through nonlesional skin, whenever possible, and change peripheral venous cannulas every 48 h
regimen Monitor fluid balance carefully: catheterize if appropriate/necessary
Establish adequate IV fluid replacement initially. Fluid replacement can be guided by urine output and other end-
point measurements. Individualized fluid management should be adjusted on a daily basis
With improvement of SJS/TEN mouth involvement, oral administration of fluids should be progressively increased
Strength of recommendation D
Nutrition regimen Provide continuous enteral nutrition throughout the acute phase
Deliver up to 2025 kcal kg 1 daily during the early, catabolic phase, and 2530 kcal kg 1 daily during the anabolic,
recovery phase
(continued)
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1221
Table 10 (continued)
Strength of recommendation C
Analgesia Use a patient-appropriate validated pain tool to assess pain in all conscious patients at least once daily
Patients should receive adequate analgesia to ensure comfort at rest, with the addition of supplementary opiates,
as required
Additional analgesia may be needed to address increased pain associated with patient handling, repositioning and
dressing changes
Strength of recommendation D (GPP)
Supportive Immobile patients should receive low molecular weight heparin
therapeutic Patients in whom enteral nutrition cannot be established should receive a proton pump inhibitor to reduce the risk
measures of stress-related gastrointestinal ulceration
Neutropenic patients may benefit from recombinant human G-CSF
Strength of recommendation C
Treatment of eye Daily ophthalmological review is necessary during the acute illness
involvement Apply an ocular lubricant (e.g. nonpreserved hyaluronate or carmellose eye drops) every 2 h through the acute
illness
Ocular hygiene must be carried out each day by an ophthalmologist or ophthalmically trained nurse
Application of topical corticosteroid drops (e.g. nonpreserved dexamethasone 0.1% twice daily) may reduce ocular
surface damage
Administer a broad-spectrum topical antibiotic as prophylaxis (e.g. moxifloxacin drops four times daily) in the
presence of corneal fluorescein staining or frank ulceration
In the unconscious patient, prevention of corneal exposure is essential
Strength of recommendation D (GPP)
Treatment of Daily oral review is necessary during the acute illness
mouth Apply white soft paraffin ointment to the lips every 2 h through the acute illness
involvement Clean the mouth daily with warm saline mouthwashes or an oral sponge
Use an anti-inflammatory oral rinse or spray containing benzydamine hydrochloride every 3 h, particularly before
eating
Use an antiseptic oral rinse containing chlorhexidine twice daily
Use a potent topical corticosteroid mouthwash (e.g. betamethasone sodium phosphate) four times daily
Strength of recommendation D (GPP)
Treatment of Daily urogenital review is necessary during the acute illness
urogenital Apply white soft paraffin ointment to the urogenital skin and mucosae every 4 h through the acute illness
involvement Use a potent topical corticosteroid ointment once daily to the involved, but noneroded, surfaces
Use a silicone dressing (e.g. MepitelTM) to eroded areas
Strength of recommendation D (GPP)
Treatment of Respiratory symptoms and hypoxaemia on admission should prompt early discussion with an intensivist and rapid
airway transfer to an ICU or burn centre, where fibreoptic bronchoscopy should be undertaken
involvement Strength of recommendation D (GPP)
Active therapy If active therapy is instituted it should be given, ideally, under the supervision of a specialist skin failure MDT in
the context of clinical research and/or case registry
Strength of recommendation D
Discharge and Give the patient written information about drug(s) to avoid
follow-up Encourage the patient to wear a MedicAlert bracelet
Drug allergy should be documented in the patients notes; all doctors involved in the patients care should be
informed
Report the episode to the national pharmacovigilance authorities
Organize a dermatology outpatient clinic appointment, and, if required, a n ophthalmology outpatient
appointment,
within a few weeks of discharge
Refer for review to unit with appropriate subspeciality interest
Strength of recommendation D (GPP)
Diagnostic testing Routine drug hypersensitivity testing is not recommended following an episode of SJS/TEN
Seek specialist advice on hypersensitivity testing where (i) the culprit drug is not known or (ii) medication
avoidance is detrimental to the individual or (iii) accidental exposure is possible
Strength of recommendation D (GPP)
FBC, full blood count; U&E, urea and electrolytes; LFT, liver function tests; CXR, chest X-ray; GPP, good practice point; BSA, body surface
area; ICU, intensive care unit; SJS/TEN, StevensJohnson syndrome/toxic epidermal necrolyis; MDT, multidisciplinary team; IV, intravenous;
G-CSF, granulocyte colony-stimulating factor.
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1222 Guidelines for SJS/TEN 2016, D. Creamer et al.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1223
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1224 Guidelines for SJS/TEN 2016, D. Creamer et al.
33 Trent JT, Kirsner RS, Romanelli P et al. Use of SCORTEN to accu- necrolysis and other blistering diseases (in French). Ann Dermatol
rately predict mortality in patients with toxic epidermal necrolysis Venereol 2011; 138:6947.
in the United States. Arch Dermatol 2004; 140:8902. 57 Yang Y-X, Lewis JD. Prevention and treatment of stress ulcers in
34 Kim KJ, Lee DP, Suh HS et al. Toxic epidermal necrolysis: analysis critically ill patients. Semin Gastrointest Dis 2003; 14:1119.
of clinical course and SCORTEN-based comparison of mortality 58 de Sica-Chapman A, Williams G, Soni N et al. Granulocyte colony-
rate and treatment modalities in Korean patients. Acta Derm Venereol stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea
2005; 85:497502. & Westminster TEN protocol. Br J Dermatol 2010; 162:8605.
35 Cartotto R, Mayich M, Nickerson D et al. SCORTEN accurately 59 Gueudry J, Roujeau JC, Binaghi M et al. Risk factors for the devel-
predicts mortality among toxic epidermal necrolysis patients trea- opment of ocular complications of Stevens-Johnson syndrome
ted in a burn center. J Burn Care Res 2008; 29:1416. and toxic epidermal necrolysis. Arch Dermatol 2009; 145:15762.
36 Rajaratnam R, Mann C, Balasubramaniam P et al. Toxic epidermal 60 Power WJ, Ghoraishi M, Merayo-Lloves J et al. Analysis of the
necrolysis: retrospective analysis of 21 consecutive cases managed acute ophthalmic manifestations of the erythema multiforme/
at a tertiary centre. Clin Exp Dermatol 2010; 35:85362. StevensJohnson syndrome/toxic epidermal necrolysis disease
37 Morales ME, Purdue GF, Verity SM et al. Ophthalmic manifesta- spectrum. Ophthalmology 1995; 102:166976.
tions of Stevens-Johnson syndrome and toxic epidermal necrolysis 61 Yip LW, Thong BY, Lim J et al. Ocular manifestations and com-
and relation to SCORTEN. Am J Ophthalmol 2010; 150:50510. plications of Stevens-Johnson syndrome and toxic epidermal
38 McGee T, Munster A. Toxic epidermal necrolysis syndrome: mor- necrolysis: an Asian series. Allergy 2007; 62:52731.
tality rate reduced with early referral to regional burn center. Plast 62 Sotozono C, Ueta M, Nakatani E et al. Predictive factors associated
Reconstr Surg 1998; 102:101822. with acute ocular involvement in Stevens-Johnson syndrome and
39 Palmieri TL, Greenhalgh DG, Saffle JR et al. A multicenter review toxic epidermal necrolysis. Am J Ophthalmol 2015; 160(228237):e2.
of toxic epidermal necrolysis treated in U.S. burn centers at the 63 Kim DH, Yoon KC, Seo KY et al. The role of systemic
end of the twentieth century. J Burn Care Rehabil 2002; 23:8796. immunomodulatory treatment and prognostic factors on chronic
40 Mahar PD, Wasiak J, Hii B et al. A systematic review of the man- ocular complications in Stevens-Johnson syndrome. Ophthalmology
agement and outcome of toxic epidermal necrolysis treated in 2015; 122:25464.
burns centres. Burns 2014; 40:124554. 64 Koroloff N, Boots R, Lipman J et al. A randomised controlled
41 Herndon DN. Mediators of metabolism. J Trauma 1981; 21:7015. study of the efficacy of hypromellose and Lacri-Lube combination
42 Herndon DN, Tompkins RG. Support of the metabolic response versus polyethylene/Cling wrap to prevent corneal epithelial
to burn injury. Lancet 2004; 363:1895902. breakdown in the semiconscious intensive care patient. Intensive
43 Brown D. How far would you go to save someones skin? Dermatol Care Med 2004; 30:11226.
Nursing 2009; 8:1019. 65 Rosenberg JB, Eisen LA. Eye care in the intensive care unit: narra-
44 Abela C, Hartmann CE, De Leo A et al. Toxic epidermal necrolysis tive review and meta-analysis. Crit Care Med 2008; 36:31515.
(TEN): The Chelsea and Westminster Hospital wound manage- 66 Sotozono C, Ueta M, Koizumi N et al. Diagnosis and treatment of
ment algorithm. J Plast Reconstr Aesthet Surg 2014; 67:102632. Stevens-Johnson syndrome and toxic epidermal necrolysis with
45 Dorafshar AH, Dickie SR, Cohn AB et al. Antishear therapy for ocular complications. Ophthalmology 2009; 116:68590.
toxic epidermal necrolysis: an alternative treatment approach. Plast 67 Araki Y, Sotozono C, Inatomi T et al. Successful treatment of Ste-
Reconstr Surg 2008; 122:15460. vens-Johnson syndrome with steroid pulse therapy at disease
46 Stella M, Clemente A, Bollero D et al. Toxic epidermal necrolysis onset. Am J Ophthalmol 2009; 147:100411.
(TEN) and Stevens-Johnson syndrome (SJS): experience with 68 Yip LW, Thong BY, Tan AW et al. High-dose intravenous
high-dose intravenous immunoglobulins and topical conservative immunoglobulin in the treatment of toxic epidermal necrolysis: a
approach. A retrospective analysis. Burns 2007; 33:4529. study of ocular benefits. Eye 2005; 19:84653.
47 Dillon CK, Lloyd MS, Dzeiwulski P. Accurate debridement of 69 John T, Foulks GN, John ME et al. Amniotic membrane in the
toxic epidermal necrolysis using Versajet. Burns 2010; 36:5814. surgical management of acute toxic epidermal necrolysis. Ophthal-
48 de Prost N, Ingen-Housz-Oro S, Duong TA et al. Bacteremia in mology 2002; 109:35160.
Stevens-Johnson syndrome and toxic epidermal necrolysis: epi- 70 Gregory DG. Treatment of acute Stevens-Johnson syndrome and
demiology, risk factors, and predictive value of skin cultures. Med- toxic epidermal necrolysis using amniotic membrane: a review of
icine 2010; 89:2836. 10 consecutive cases. Ophthalmology 2011; 118:90814.
49 Baker RH, Akhavani MA, Jallali N. Resuscitation of thermal inju- 71 Shammas MC, Lai EC, Sarkar JS et al. Management of acute Ste-
ries in the United Kingdom and Ireland. J Plast Reconstr Aesthet Surg vens-Johnson syndrome and toxic epidermal necrolysis utilizing
2007; 60:6825. amniotic membrane and topical corticosteroids. Am J Ophthalmol
50 Shiga S, Cartotto R. What are the fluid requirements in toxic epi- 2010; 149:20313.
dermal necrolysis? J Burn Care Res 2010; 31:1004. 72 Kobayashi A, Yoshita T, Sugiyama K et al. Amniotic membrane
51 Coss-Bu JA, Jefferson LS, Levy ML et al. Nutrition requirements in transplantation in acute phase of toxic epidermal necrolysis with
patients with toxic epidermal necrolysis. Nutr Clin Pract 1997; severe corneal involvement. Ophthalmology 2006; 113:12632.
12:814. 73 Shay E, Kheirkhah A, Liang L et al. Amniotic membrane transplan-
52 Hansbrough JF, Muller P, Noordenbos J et al. A 10-year experience tation as a new therapy for the acute ocular manifestations of Ste-
with toxic epidermal necrolysis. J Burn Care Rehabil 2001; 22:978. vens-Johnson syndrome and toxic epidermal necrolysis. Surv
53 Lacy JA. Toxic epidermal necrolysis. Nutr Clin Pract 1991; 6:1820. Ophthalmol 2009; 54:68696.
54 Kreymann KG, Berger MM, Deutz NE et al. ESPEN guidelines on 74 Tomlins PJ, Parulekar MV, Rauz S. Triple-TEN in the treatment
enteral nutrition: intensive care. Clin Nutr 2006; 25:21023. of acute ocular complications from toxic epidermal necrolysis.
55 World Health Organization. Cancer Pain Relief, with a Guide to Opioid Cornea 2013; 32:3659.
Availability. Geneva: World Health Organization, 1996. 75 Kolomeyer AM, Do BK, Tu Y et al. Placement of ProKera in the
56 Valeyrie-Allanore L, Ingen-Housz-Oro S, Colin A et al. Pain man- management of ocular manifestations of acute Stevens-Johnson
agement in StevensJohnson syndrome, toxic epidermal syndrome in an outpatient. Eye Contact Lens 2013; 39:e711.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1225
76 Hsu M, Jayaram A, Verner R et al. Indications and outcomes of multicenter retrospective analysis of 48 consecutive cases. Arch
amniotic membrane transplantation in the management of acute Dermatol 2003; 139:2632.
Stevens-Johnson syndrome and toxic epidermal necrolysis: a 96 Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin
casecontrol study. Cornea 2012; 31:1394402. treatment for Stevens-Johnson syndrome and toxic epidermal
77 Ciralsky JB, Sippel KC. Prompt versus delayed amniotic mem- necrolysis: a prospective noncomparative study showing no bene-
brane application in a patient with acute Stevens-Johnson syn- fit on mortality or progression. Arch Dermatol 2003; 139:336.
drome. Clin Ophthalmol 2013; 7:10314. 97 Campione E, Marulli GC, Carrozzo AM et al. High-dose intra-
78 Muqit MM, Ellingham RB, Daniel C. Technique of amniotic venous immunoglobulin for severe drug reactions: efficacy in
membrane transplant dressing in the management of acute Ste- toxic epidermal necrolysis. Acta Derm Venereol 2003; 83:4302.
vens-Johnson syndrome. Br J Ophthalmol 2007; 91:1536. 98 Al-Mutairi N, Arun J, Osama NE et al. Prospective, noncompara-
79 Patel BC, Sapp NA, Collin R. Standardized range of conformers tive open study from Kuwait of the role of intravenous
and symblepharon rings. Ophthal Plast Reconstr Surg 1998; 14: immunoglobulin in the treatment of toxic epidermal necrolysis.
1445. Int J Dermatol 2004; 43:84751.
80 Liang X, Liu Z, Lin Y et al. A modified symblepharon ring for 99 Brown KM, Silver GM, Halerz M et al. Toxic epidermal necrolysis:
sutureless amniotic membrane patch to treat acute ocular surface does immunoglobulin make a difference? J Burn Care Rehabil 2004;
burns. J Burn Care Res 2012; 33:e328. 25:818.
81 Sedghizadeh PP, Kumar SK, Gorur A et al. Toxic epidermal necrol- 100 Shortt R, Gomez M, Mittman N et al. Intravenous immunoglobu-
ysis with a rare long-term oral complication requiring surgical lin does not improve outcome in toxic epidermal necrolysis. J
intervention. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; Burn Care Rehabil 2004; 25:24655.
105:e2933. 101 Tan AW, Thong BY, Yip LW et al. High-dose intravenous
82 Roujeau JC, Phlippoteau C, Koso M et al. Sjogren-like syndrome immunoglobulins in the treatment of toxic epidermal necrolysis:
after drug-induced toxic epidermal necrolysis. Lancet 1985a; an Asian series. J Dermatol 2005; 32:16.
1:60911. 102 Gravante G, Delogu D, Marianetti M et al. Toxic epidermal necrol-
83 Lozada-Nur F, Huang MZ, Zhou GA. Open preliminary clinical ysis and Steven Johnson syndrome: 11-years experience and out-
trial of clobetasol propionate ointment in adhesive paste for treat- come. Eur Rev Med Pharmacol Sci 2007; 11:11927.
ment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med 103 Firoz BF, Henning JS, Zarzabal LA et al. Toxic epidermal necroly-
Oral Pathol 1991; 71:2837. sis: five years of treatment experience from a burn unit. J Am Acad
84 Sanchis JM, Bagan JV, Gavalda C et al. Erythema multiforme: diag- Dermatol 2012; 67:6305.
nosis, clinical manifestations and treatment in a retrospective 104 Lee HY, Lim YL, Thirumoorthy T et al. The role of intravenous
study of 22 patients. J Oral Pathol Med 2010; 39:74752. immunoglobulin in toxic epidermal necrolysis: a retrospective
85 Meneux E, Paniel BJ, Pouget F et al. Vulvovaginal sequelae in analysis of 64 patients managed in a specialized centre. Br J Der-
toxic epidermal necrolysis. J Reprod Med 1997; 42:1536. matol 2013; 169:13049.
86 Rowan DM, Jones RW, Oakley A et al. Vaginal stenosis after toxic 105 Aihara M, Kano Y, Fujita H et al. Efficacy of additional i.v.
epidermal necrolysis. J Low Genit Tract Dis 2010; 14:3902. immunoglobulin to steroid therapy in Stevens-Johnson syndrome
87 Niemeijer IC, van Praag MC, van Gemund N. Relevance and con- and toxic epidermal necrolysis. J Dermatol 2015; 42:76877.
sequences of erythema multiforme, Stevens-Johnson syndrome 106 Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobu-
and toxic epidermal necrolysis in gynecology. Arch Gynecol Obstet lin for the treatment of toxic epidermal necrolysis: a systematic review
2009; 280:8514. and meta-analysis. Br J Dermatol 2012; 167:42432.
88 Meneux E, Wolkenstein P, Haddad B et al. Vulvovaginal involve- 107 Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Ste-
ment in toxic epidermal necrolysis: a retrospective study of 40 vens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm
cases. Obstet Gynecol 1998; 91:2837. Venereol 2007; 87:1448.
89 Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal 108 Tripathi A, Ditto AM, Grammer LC et al. Corticosteroid therapy in
sequelae in Stevens-Johnson syndrome and toxic epidermal an additional 13 cases of Stevens-Johnson syndrome: a total series
necrolysis. Rev Obstet Gynecol 2011; 4:815. of 67 cases. Allergy Asthma Proc 2000; 21:1015.
90 Lebargy F, Wolkenstein P, Gisselbrecht M et al. Pulmonary com- 109 Yang Y, Xu J, Li F et al. Combination therapy of intravenous
plications in toxic epidermal necrolysis: a prospective clinical immunoglobulin and corticosteroid in the treatment of toxic epi-
study. Intensive Care Med 1997; 23:123744. dermal necrolysis and Stevens-Johnson syndrome: a retrospective
91 Kamada N, Kinoshita K, Togawa Y et al. Chronic pulmonary com- comparative study in China. Int J Dermatol 2009; 48:11228.
plications associated with toxic epidermal necrolysis: report of a 110 Chen J, Wang B, Zeng Y et al. High-dose intravenous
severe case with anti-Ro/SS-A and a review of the published immunoglobulins in the treatment of Stevens-Johnson syndrome
work. J Dermatol 2006; 33:61622. and toxic epidermal necrolysis in Chinese patients: a retrospective
92 Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised compar- study of 82 cases. Eur J Dermatol 2010; 20:7437.
ison of thalidomide versus placebo in toxic epidermal necrolysis. 111 Murphy JT, Purdue GF, Hunt JL. Toxic epidermal necrolysis. J
Lancet 1998; 352:15869. Burn Care Rehabil 1997; 18:41720.
93 Stella M, Cassano P, Bollero D et al. Toxic epidermal necrolysis 112 Hirahara K, Kano Y, Sato Y et al. Methylprednisolone pulse ther-
treated with intravenous high-dose immunoglobulins: our experi- apy for Stevens-Johnson syndrome/toxic epidermal necrolysis:
ence. Dermatology 2001; 203:459. clinical evaluation and analysis of biomarkers. J Am Acad Dermatol
94 Trent JT, Kirsner RS, Romanelli P et al. Analysis of intravenous 2013; 69:4968.
immunoglobulin for the treatment of toxic epidermal necrolysis 113 Arevalo JM, Lorente JA, Gonzalez-Herrada C et al. Treatment of toxic
using SCORTEN: The University of Miami Experience. Arch Derma- epidermal necrolysis with cyclosporin A. J Trauma 2000; 48:4738.
tol 2003; 139:3943. 114 Valeyrie-Allanore L, Wolkenstein P, Brochard L et al. Open trial of
95 Prins C, Kerdel FA, Padilla RS et al. Treatment of toxic epidermal ciclosporin treatment for Stevens-Johnson syndrome and toxic
necrolysis with high-dose intravenous immunoglobulins: epidermal necrolysis. Br J Dermatol 2010; 163:84753.
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227
1226 Guidelines for SJS/TEN 2016, D. Creamer et al.
115 Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens John- 134 Polak ME, Belgi G, McGuire C et al. In vitro diagnostic assays are
son syndrome and toxic epidermal necrolysis and retrospective effective during the acute phase of delayed-type drug hypersensi-
comparison with systemic corticosteroid. Indian J Dermatol Venereol tivity reactions. Br J Dermatol 2013; 168:53949.
Leprol 2013; 79:68692. 135 Valeyrie-Allanore L, Mockenhaupt M, Sekula P et al. Mechanisms
116 Kirchhof MG, Miliszewski MA, Sikora S et al. Retrospective review that limit proliferative potential of drug-specific LTT in drug-
of Stevens-Johnson syndrome/toxic epidermal necrolysis treat- induced severe cutaneous adverse reaction patients. Clin Transl
ment comparing intravenous immunoglobulin with cyclosporine. Allergy 2014; 4:1.
J Am Acad Dermatol 2014; 71:9417. 136 Zawodniak A, Lochmatter P, Yerly D et al. In vitro detection of
117 Narita YM, Hirahara K, Mizukawa Y et al. Efficacy of plasma- cytotoxic T and NK cells in peripheral blood of patients with var-
pheresis for the treatment of severe toxic epidermal necrolysis: is ious drug-induced skin diseases. Allergy 2010; 65:37684.
cytokine expression analysis useful in predicting its therapeutic 137 Rozieres A, Hennino A, Rodet K et al. Detection and quantifica-
efficacy? J Dermatol 2011; 38:23645. tion of drug-specific T cells in penicillin allergy. Allergy 2009;
118 Kostal M, Blaha M, Lanska M et al. Beneficial effect of plasma 64:53442.
exchange in the treatment of toxic epidermal necrolysis: a series 138 Lochmatter P, Beeler A, Kawabata TT et al. Drug-specific in vitro
of four cases. J Clin Apher 2012; 27:21520. release of IL-2, IL-5, IL-13 and IFN-gamma in patients with
119 Paradisi A, Abeni D, Bergamo F et al. Etanercept therapy for toxic delayed-type drug hypersensitivity. Allergy 2009; 64:126978.
epidermal necrolysis. J Am Acad Dermatol 2014; 71:27883. 139 Sachs B, Erdmann S, Malte Baron J et al. Determination of inter-
120 National Institute for Health and Care Excellence. Drug allergy: leukin-5 secretion from drug-specific activated ex vivo peripheral
diagnosis and management of drug allergy in adults, children blood mononuclear cells as a test system for the in vitro detection
and young people. Available at: https://www.nice.org.uk/guid- of drug sensitization. Clin Exp Allergy 2002; 32:73644.
ance/cg183 (last accessed 16 February 2016). 140 Halevy S, Grossman N. Multiple drug allergy in patients with cuta-
121 Butt TF, Cox AR, Lewis H et al. Patient experiences of serious neous adverse drug reactions diagnosed by in vitro drug-induced
adverse drug reactions and their attitudes to medicines: a qualita- interferon-gamma release. Isr Med Assoc J 2008; 10:8658.
tive study of survivors of Stevens-Johnson syndrome and toxic 141 Fu M, Gao Y, Pan Y et al. Recovered patients with Stevens-Johson
epidermal necrolysis in the UK. Drug Saf 2011; 34:31928. syndrome and toxic epidermal necrolysis maintain long-lived
122 Sotozono C, Ang LP, Koizumi N et al. New grading system for IFN-c and sFasL memory response. PLoS ONE 2012; 7:e45516.
the evaluation of chronic ocular manifestations in patients with 142 Haute Autorite de Sante. Necrolyse epidermique toxique (syn-
Stevens-Johnson syndrome. Ophthalmology 2007; 114:1294302. dromes de StevensJohnson et de Lyell): Protocole national de
123 Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr diagnostic et de soins. 2010: Available at: http://www.has-san-
Opin Allergy Clin Immunol 2010; 10:2916. te.fr/portail/upload/docs/application/pdf/2011-01/ald_31_
124 Wolkenstein P, Chosidow O, Flechet ML et al. Patch testing in pnds_sjs_lyell_web.pdf (last accessed 16 February 2016).
severe cutaneous adverse drug reactions, including Stevens-John-
son syndrome and toxic epidermal necrolysis. Contact Dermatitis
1996; 35:2346. Appendix 1
125 Lin YT, Chang YC, Hui RC et al. A patch testing and cross-sensi-
Levels of evidence
tivity study of carbamazepine-induced severe cutaneous adverse
drug reactions. J Eur Acad Dermatol Venereol 2013; 27:35664.
Level of
126 Barbaud A, Collet E, Milpied B et al. A multicentre study to deter-
evidencea Type of evidence
mine the value and safety of drug patch tests for the three main
classes of severe cutaneous adverse drug reactions. Br J Dermatol 1++ High-quality meta-analyses, systematic reviews of
2013; 168:55562. RCTs or RCTs with a very low risk of bias
127 Neukomm CB, Yawalkar N, Helbling A et al. T-cell reactions to 1+ Well-conducted meta-analyses, systematic reviews
drugs in distinct clinical manifestations of drug allergy. J Investig of RCTs or RCTs with a low risk of bias
Allergol Clin Immunol 2001; 11:27584. 1 Meta-analyses, systematic reviews of RCTs or RCTs
128 Hari Y, Frutig-Schnyder K, Hurni M et al. T cell involvement in with a high risk of bias
cutaneous drug eruptions. Clin Exp Allergy 2001; 31:1398408. 2++ High-quality systematic reviews of casecontrol or
129 Kano Y, Hirahara K, Mitsuyama Y et al. Utility of the lymphocyte cohort studies. High-quality casecontrol or cohort
transformation test in the diagnosis of drug sensitivity: dependence on studies with a very low risk of confounding, bias or
its timing and the type of drug eruption. Allergy 2007; 62:143944. chance, and a high probability that the relationship
130 Tang YH, Mockenhaupt M, Henry A et al. Poor relevance of a is causal
lymphocyte proliferation assay in lamotrigine-induced Stevens- 2+ Well-conducted casecontrol or cohort studies with a
Johnson syndrome or toxic epidermal necrolysis. Clin Exp Allergy low risk of confounding, bias or chance, and a
2012; 42:24854. moderate probability that the relationship is causal
131 Roujeau JC, Albengres E, Moritz S et al. Lymphocyte transforma- 2 Casecontrol or cohort studies with a high risk of
tion test in drug-induced toxic epidermal necrolysis. Int Arch confounding, bias or chance, and a significant risk
Allergy Appl Immunol 1985b; 78:224. that the relationship is not causal
132 Nyfeler B, Pichler WJ. The lymphocyte transformation test for 3 Nonanalytical studies (e.g. case reports, case series)
the diagnosis of drug allergy: sensitivity and specificity. Clin Exp 4 Expert opinion, formal consensus
Allergy 1997; 27:17581.
RCT, randomized controlled trials. aStudies with a level of evi-
133 Porebski G, Pecaric-Petkovic T, Groux-Keller M et al. In vitro drug
dence should not be used as a basis for making a recom-
causality assessment in Stevens-Johnson syndrome alternatives
for lymphocyte transformation test. Clin Exp Allergy 2013; mendation.Strength of recommendation
43:102737.
British Journal of Dermatology (2016) 174, pp11941227 2016 British Association of Dermatologists
Guidelines for SJS/TEN 2016, D. Creamer et al. 1227
2016 British Association of Dermatologists British Journal of Dermatology (2016) 174, pp11941227